Comparative Pharmacology
Head-to-head clinical analysis: LACRISERT versus VEVYE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LACRISERT versus VEVYE.
LACRISERT vs VEVYE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LACRISERT (hydroxypropyl cellulose ophthalmic insert) acts as a lubricant to stabilize and thicken the precorneal tear film, prolonging tear film breakup time and protecting the ocular surface. It does not have pharmacological activity.
Vevye (cyclosporine ophthalmic solution) is a calcineurin inhibitor immunosuppressant. It inhibits T-cell activation by binding to cyclophilin, forming a complex that blocks calcineurin, thereby preventing dephosphorylation and nuclear translocation of nuclear factor of activated T-cells (NFAT), reducing pro-inflammatory cytokine production (e.g., IL-2). In ocular tissues, it suppresses inflammation and immune-mediated responses, increasing tear production through anti-inflammatory effects on lacrimal glands.
One 5 mg ophthalmic insert placed into the inferior cul-de-sac of the eye once daily.
VEVYE (voclosporin) 23.7 mg orally twice daily in combination with mycophenolate mofetil and corticosteroids.
None Documented
None Documented
Not applicable; local ocular insert, no systemic half-life.
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 24-30 hours in renal impairment (CrCl <30 mL/min)
Not systemically absorbed; no renal or biliary elimination.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Ophthalmic Lubricant
Ophthalmic Lubricant